Tegoprazan

Tegoprazan is a novel patented Potassium-Competitive Acid Blocker (P-CAB) which alleviates the limitations of the historical Proton Pump Inhibitors (PPIs) and of other competing P-CABs. 

Tegoprazan's competitive advantages have been demonstrated via Phase 3 clinical studies conducted in Korea and Phase 1 clinical study from the US. 


Based on the outstanding achievements, Tegoprazan was approved by MFDS in 2019 under four (4) indications: Erosive Reflux Disease (ERD), Non-Erosive Gastro Esophageal Reflux Disease (NERD), Gastric Ulcer (GU) and Helicobacter pylori Eradication. 


Other than in South Korea, Tegoprazan received approval in China, Mongolia and Philippines among the 34 countries where HK inno.N has licensed out to.


HK inno.N is actively searching for business partners whom they can develop Tegoprazan in unpartnered counties. For further information, please contact Ga-Young Lee (BD, [email protected])